NOT MEDICAL ADVICE

PE-22-28

Estimated Market Price
$89.99 $104.99
Based on verified supplier pricing for research-grade compounds
TREK-1 channel blocker with rapid antidepressant and nootropic effects. Upregulates BDNF and stimulates hippocampal neurogenesis for mood and cognition.
How it works

Activates delta-opioid receptors to produce mood-lifting and anxiety-reducing effects without the addictive properties tied to mu-opioid pathways. May also enhance brain plasticity through BDNF signaling.

Focus & Cognition

What to Expect
Days 1–3 Delta-opioid receptor modulation begins; subtle mood lift. Subtle mood lift; feeling slightly more optimistic.
Week 1–2 Anxiolytic effects emerging; stress response dampening. Anxiety reducing; motivation starting to increase.
Week 3–4 Antidepressant effects consolidating; BDNF pathway active. Mood significantly better; feeling more engaged and present.
Week 5–8 Peak mood and neuroplasticity benefits; stable emotional state. Stable good mood; emotional resilience notably improved.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier
Protocol & Dosage
Typical Dosage 200–400 mcg SC daily
Administration Intranasal, Subcutaneous injection
Schedule Once daily, AM preferred
Protocol Duration 4–8 weeks
Half-Life Not well established
Side Effects & Safety
Tolerability Profile Moderate

Notable side effects likely; manageable with proper awareness

Common Side Effects

  • No common side effects reported

Less Common

  • Headacheoccasional
  • GI discomfortoccasional
  • Mood changesoccasional

Discontinue If

  • Signs of opioid-like effects (respiratory depression, excessive sedation)
  • Severe mood changes or emotional instability
  • Signs of dependence or withdrawal

Contraindications

  • History of opioid addiction
  • Concurrent opioid medications
  • Pregnancy or breastfeeding
  • Severe depression (unmonitored)

Data note: Acts on TREK-1 potassium channels (opioid-adjacent pathways). Preclinical only — virtually no human safety data exists.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about PE-22-28
Send us a message

Call us
+1 (518) 327-4392
Business hours
Monday – Friday 9:00 AM – 6:00 PM EST
Saturday 10:00 AM – 2:00 PM EST
Sunday Closed

You can also reach us via or .

How to Apply

1

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

2

Sanitize

Wipe tops of both vials with alcohol swabs

3

Draw

Pull 1–2 mL of BAC water into syringe

4

Add Water

Release water slowly along vial wall, not directly on powder

5

Swirl

Roll between palms until dissolved. Never shake.

6

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for PE-22-28

Also Known As PE-22-28, Proenkephalin Fragment
Classification Heptapeptide · Antidepressant / Mood Regulator
Sequence Fragment of proenkephalin (residues 22-28)
Molecular Formula Heptapeptide
Molecular Weight ~800 Da
CAS Number N/A
Half-Life Not well established
Origin Derived from proenkephalin A precursor protein
Administration Intranasal, Subcutaneous injection
Status Research compound - preclinical
Mechanism of Action Activates delta-opioid receptors to produce mood-lifting and anxiety-reducing effects without the addictive properties tied to mu-opioid pathways. May also enhance brain plasticity through BDNF signaling.
Research Overview PE-22-28 is a heptapeptide fragment derived from proenkephalin A (PENK), the precursor protein that gives rise to the endogenous opioid peptides met-enkephalin and leu-enkephalin through proteolytic processing. The fragment corresponds to residues 22-28 of the proenkephalin sequence - a region that lies outside the classical enkephalin-encoding domains and was not initially expected to possess significant biological activity. However, research into non-opioid fragments of opioid precursor proteins has revealed a rich pharmacology beyond the well-characterized enkephalin peptides, with several proenkephalin-derived fragments demonstrating biological activities mediated through receptors and mechanisms distinct from the classical mu, delta, and kappa opioid receptors. PE-22-28 has attracted particular attention for its antidepressant-like and anxiolytic properties observed in preclinical behavioral models. In rodent studies, PE-22-28 administration reduced immobility time in the forced swim test and tail suspension test - established behavioral paradigms for assessing antidepressant potential - and decreased anxiety-like behavior in the elevated plus maze and light-dark box tests, without producing the sedation, motor impairment, or reward-related behaviors associated with classical opioid agonists. The proposed mechanism involves modulation of the delta-opioid receptor system, which has been increasingly recognized as a target for antidepressant and anxiolytic drug development. Delta-opioid receptor activation produces mood-elevating and anxiolytic effects through enhancement of BDNF expression in the hippocampus and prefrontal cortex, stimulation of hippocampal neurogenesis, and modulation of the mesolimbic dopamine reward circuitry. Unlike mu-opioid receptor agonists, delta-opioid agonists generally lack the reinforcing properties and physical dependence liability that limit the utility of traditional opioids for mood disorders.

Citations

Published findings on PE-22-28 from peer-reviewed journals.

Research Assistant
Hey, I'm the PepSpace research assistant. Ask me anything about peptides and I'll do my best to help.